摘要
目的探讨抑癌基因P16(P16)、增殖细胞相关抗原(Ki67)在宫颈癌组织中表达水平及其与临床特征、预后的关系。方法选取我院收治的宫颈癌患者82例,用免疫组织化学法检测癌组织及癌旁正常组织中的P16、Ki67的表达。分析P16、Ki67在宫颈癌组织中表达水平及其与临床特征、预后的关系。结果癌组织P16、Ki67的阳性表达率分别为74.39%、70.73%,高于癌旁组织的18.29%、20.73%(P<0.05)。肿瘤大小>4 cm、TNM分期T3期、浸润深度>1/3肌层癌组织P16、Ki67阳性表达率分别为90.91%、87.88%,92.11%、94.74%,90.91%、90.91%,高于肿瘤大小≤4 cm、TNM分期T1~T2期、浸润深度≤1/3肌层癌组织的63.27%、59.18%,59.09%、50.00%,68.33%、63.33%(P<0.05)。非术后1年无进展生存宫颈癌患者宫颈癌组织P16、Ki67表达阳性率95.24%、90.48%,高于术后1年无进展生存宫颈癌患者的67.21%、63.93%(P<0.05)。结论P16、Ki67在宫颈癌组织中表达增加,且与临床特征、预后密切相关。
Objective To investigate the expression levels of tumor suppressor gene P16(P16)and proliferative cell associated antigen(Ki67)in cervical cancer tissues and their relationship with clinical features and prognosis.Methods The expression of P16 and Ki67 in cancer tissues and adjacent normal tissues were detected by immunohistochemistry in 82 patients with cervical cancer treated in our hospital.To analyze the expression levels of P16 and Ki67 in cervical cancer tissues and their relationship with clinical features and prognosis.Results The positive expression rates of P16 and Ki67 in cancer tissue were 74.39% and 70.73%,respectively,compared with 18.29% and 20.73% in para-cancer tissue(P<0.05).The positive expression rates of P16 and Ki67 were 90.91%,87.88%,92.11%,94.74%,90.91%,90.91%,90.91% in myoma with tumor size>4 cm,TNM stage T3 and invasion depth>1/3,respectively,whicht was higher than 63.27%,59.18%,59.09%,50.00%,68.33%,63.33% of myoma tissues with tumor size≤4 cm,TNM stage T1~T2 and invasion depth≤1/3(P<0.05).The expression positive rates of P16 and Ki67 were 95.24% and 90.48% in patients with non-progression-free survival 1 year after surgery,higher than 67.21%and 63.93%in patients with progression-free survival 1 year after surgery(P<0.05).Conclusions The expression of P16 and Ki67 increased in cervical cancer tissue,which is closely related to clinical features and prognosis.
作者
杨柳荫
靳小飞
高云燕
YANG Liuyin;JIN Xiaofei;GAO yunyan(Pathology Department of Luoyang Maternal and Child Health Hospital,Luoyang,Henan Province,471000)
出处
《航空航天医学杂志》
2024年第10期1157-1159,共3页
Journal of Aerospace medicine
关键词
宫颈癌
抑癌基因P16
增殖细胞相关抗原
临床特征
预后
Cervical cancer
Tumor suppressor gene P16
Proliferating cell associated antigen
Clinical features
Prognosis